clinical trial · NCT04294576
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
BJ Bioscience, Inc.·phase1·unknown·n = 92
Locally Advanced/Metastatic Solid TumorsBJ-001Pembrolizumab
brief summary
The purpose of this study is to assess the safety and tolerability of BJ-001, a human IL-15 fusion protein, administered via subcutaneous injections, as a single agent and in combination with pembrolizumab in adult patients with Locally Advanced/Metastatic Solid Tumors
started
Dec 4, 2019
primary completion
Apr 29, 2024
completion
Oct 22, 2024
last updated
Nov 9, 2023
official title
First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol